Federal Register / Vol. 83, No. 15 / Tuesday, January 23, 2018 / Notices 3173 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 2101 of the Public Health 

Service Act (42 U.S.C. 300aa–1), the 

Secretary of Health and Human Services 

was mandated to establish the National 

Vaccine Program to achieve optimal 

prevention of human infectious diseases 

through immunization and to achieve 

optimal prevention against adverse 

reactions to vaccines. The NVAC was 

established to provide advice and make 

recommendations to the Director of the 

National Vaccine Program on matters 

related to the Program’s responsibilities. 

The Assistant Secretary for Health 

serves as Director of the National 

Vaccine Program. During the February 

2018 NVAC meeting, sessions will 

consist of presentations on vaccine 

innovation, including the current status 

of adjuvants in vaccines, universal 

influenza, and an overview on the 

Secretary of the Department of Health 

and Human Services’ Report to Congress 

on Vaccine Innovation in response to 

the 21st Century Cures Act; a report out 

on the recently approved Presidential 

Advisory Council on Combatting 

Antibiotic-Resistant Bacteria Report, 

‘‘Incentivizing the Development of 

Vaccines, Therapeutics, and Diagnostics 

to Combat Antibiotic Resistant 

Bacteria’’; disparities in adult 

immunizations; and an update on 

strategies to support improving coverage 

for human papillomavirus vaccine. 

Please note that agenda items will be 

related to the charge of the Committee 

and are subject to change as priorities 

dictate. Information on the final meeting 

agenda will be posted prior to the 

meeting on the NVAC website: http://

www.hhs.gov/nvpo/nvac/index.html. 

Public attendance at the meeting is 

limited to the available space. 

Individuals who plan to attend in 

person and need special assistance, 

such as sign language interpretation or 

other reasonable accommodations, 

should notify the National Vaccine 

Program Office at the address/phone 

number listed above at least one week 

prior to the meeting. For those unable to 

attend in person, a live webcast will be 

available. More information on 

registration and accessing the webcast 

can be found at http://www.hhs.gov/ 

nvpo/nvac/meetings/index.html. 

Members of the public will have the 

opportunity to provide comments at the 

NVAC meeting during the public 

comment periods designated on the 

agenda. Public comments made during 

the meeting will be limited to three 

minutes per person to ensure time is 

allotted for all those wishing to speak. 

Individuals are also welcome to submit 

their written comments. Written 

comments should not exceed three 

pages in length. Individuals submitting 

written comments should email their 

comments to the National Vaccine 

Program Office (nvpo@hhs.gov) at least 

five business days prior to the meeting. 

Dated: January 17, 2018. 

Roula Sweis, 

Deputy Director, National Vaccine Program 

Office. 

[FR Doc. 2018–01142 Filed 1–22–18; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of 

meetings of the Task Force on Research 

Specific to Pregnant Women and 

Lactating Women. 

The meetings will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Task Force on 

Research Specific to Pregnant Women 

and Lactating Women. 

Date: February 26–27, 2018. 

Time: February 26, 2018, 8:30 a.m. to 

5:00 p.m.; February 27, 2018, 8:00 a.m. 

to 3:00 p.m. 

Agenda: The Task Force is charged 

with providing advice and guidance to 

the Secretary of HHS, regarding Federal 

activities related to identifying and 

addressing gaps in knowledge and 

research regarding safe and effective 

therapies for pregnant women and 

lactating women, including the 

development of such therapies and the 

collaboration on and coordination of 

such activities. 

February 26th, 2018—Day 1 

8:30 a.m.—Welcome and Opening 

Remarks 

8:40 a.m.—Introductions 

8:45 a.m.—Summary and Discussion of 

work products from meetings 1 and 

2 

10:45 a.m.—Follow-up on Task Force 

Request regarding Lessons learned 

from Pediatrics 

1:15 p.m.—Effective communication 

strategies with health care providers 

and the public on information 

relevant to pregnant women and 

lactating women 

1:50 p.m.—Panel: Effective 

communication strategies with 

health care providers on 

information relevant to pregnant 

women and lactating women 

3:30 p.m.—Panel: Effective 

communication strategies with the 

public on information relevant to 

pregnant women and lactating 

women. 

4:10 p.m.—Discussion 

5:00 p.m.—End of Day 1 

February 27th, 2018—Day 2 

8:00 a.m.—Recap from Day 1, Outline & 

Goals of Day 2 

8:15 a.m.—Panel and open discussion to 

cover specific questions on the 

options for a plan or plans to 

identify and address gaps in 

knowledge and research regarding 

safe and effective therapies for 

pregnant women and lactating 

women, including the development 

of such therapies. 

12:45 p.m.—Discussion of Key Points 

related to topic: Effective 

communication strategies with 

health care providers and the 

public on information relevant to 

pregnant women and lactating 

women 

1:30 p.m.—Discussion of Key Points 

related to topic: A plan to identify 

and address gaps in knowledge and 

research regarding safe and 

effective therapies for pregnant 

women and lactating women, 

including the development of such 

therapies 

2:15 p.m.—Review of Recommendations 

from TF1–3 

2:45 p.m.—Action Items, Charge to 

Group 

3:00 p.m.—Adjournment 

Place: 6710B Rockledge Drive, Room 

1425/1427 (1st Floor), Bethesda, MD 

20817. 

Contact Person: Ms. Lisa Kaeser, 

Executive Secretary, Eunice Kennedy 

Shriver National Institute of Child 

Health and Human Development, 31 

Center Drive, Room 2A03, MSC 2425, 

Bethesda, MD 20892, (301) 496–0536, 

kaeserl@mail.nih.gov. 

Public comments are welcome either 

by filing written comments and/or 

providing oral comments at the meeting. 

Oral comments from the public will be 

scheduled on February 26, 2018, from 

approximately 10:00 a.m.–10:45 a.m. 

Any member of the public interested in 

presenting oral comments on February 

26, 2018, should submit a letter of 

intent, a brief description of the 

organization represented, and the oral 

presentation to Ms. Lisa Kaeser 

(Kaeserl@mail.nih.gov) by 5:00 p.m. on 

Monday, February 19, 2018. Written 


sradovich on DSK3GMQ082PROD with NOTICES
3174 Federal Register / Vol. 83, No. 15 / Tuesday, January 23, 2018 / Notices 

comments to be included at the meeting 

should also be sent to Lisa Kaeser by 

5:00 p.m. on Monday, February 19, 

2018. 

The submitted presentations and any 

written comments will be formatted to 

be posted on the PRGLAC website for 

the record. Only one representative of 

an organization may be allowed to 

present oral comments. Presentations 

will be limited to three to five minutes 

per speaker depending on the number of 

speakers to be accommodated within 

the allotted time. Speakers will be 

assigned a time to speak in the order of 

the date and time when their request to 

speak is received. Both printed and 

electronic copies are requested for the 

record. 

Details and additional information 

about these meetings can be found at the 

NICHD website for the Task Force on 

Research Specific to Pregnant Women 

and Lactating Women (PRGLAC) 

https://www.nichd.nih.gov/about/ 

advisory/PRGLAC/Pages/index.aspx. 

Dated: January 17, 2018. 

Michelle Trout, 

Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–01082 Filed 1–22–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Epilepsy: 

Molecular Mechanisms. 

Date: January 24, 2018. 

Time: 3:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Suzan Nadi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217B, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1259, nadis@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 17, 2018. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–01077 Filed 1–22–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Radiation Therapeutics and Biology 

Study Section. 

Date: February 12–13, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW, 

Washington, DC 20015. 

Contact Person: Bo Hong, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 6194, MSC 7804, Bethesda, MD 

20892, 301–996–6208, hongb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–RM– 

17–030: Novel and Innovative Tools to 

Facilitate Identification, Tracking, 

Manipulation, and Analysis of Glycans and 

their Functions. 

Date: February 15, 2018. 

Time: 10:00 a.m. to 3:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Marie-Jose Belanger, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm 6188 MSC 

7804, Bethesda, MD 20892, 301–435–1267, 

belangerm@csr.nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; 

Therapeutic Approaches to Genetic Diseases 

Study Section. 

Date: February 15, 2018. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Methode Bacanamwo, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2200, 

Bethesda, MD 20892, 301–827–7088, 

methode.bacanamwo@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–RM– 

17–029: Innovative Adaptations to Simplify 

Existing Technologies for Manipulation and 

Analysis of Glycans. 

Date: February 15, 2018. 

Time: 3:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Marie-Jose Belanger, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm 6188 MSC 

7804, Bethesda, MD 20892, 301–435–1267, 

belangerm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Screenable Disorders: Therapeutics, Tools 

and Natural History. 

Date: February 16, 2018. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Methode Bacanamwo, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2200, 

Bethesda, MD 20892, 301–827–7088, 

methode.bacanamwo@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Cardiovascular Disorders. 

Date: February 21, 2018. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Luis Espinoza, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 


sradovich on DSK3GMQ082PROD with NOTICES